Frontiers in Cardiovascular Medicine

FEBRUARY 11, 2024

At present we do not have any reliable intra-procedural electrophysiologic predictors of long-term success of AF ablation other than pulmonary vein isolation. We evaluated selected intraprocedural pulmonary vein characteristics that may be helpful in future guidance of persistent AF ablation. Results PV capture was identified in 20.3%

Pulmonary 64

Pulmonary Ablation Atrial Fibrillation Electrophysiology 64

Circulation: Cardiovascular Interventions

DECEMBER 27, 2024

BACKGROUND:Varying rates of nonsustained ventricular tachycardia (NSVT) have been reported early after transcatheter pulmonary valve replacement (TPVR) with the Harmony valve, but data regarding rhythm outcomes beyond hospital discharge are limited.

Pulmonary 40

Pulmonary Arrhythmia Cardiovascular Interventions Tachycardia 40

DAIC

MAY 18, 2024

Atrial fibrillation is the most common type of arrhythmia, and by 2050, up to 16 million Americans are projected to have AF 1. Pulmonary vein isolation (PVI) procedure, left atrial dwell, and fluoroscopy times were 51, 32, and 12 minutes, respectively. Lucas Boersma , electrophysiologist, St.

Heart Rhythm 105

Heart Rhythm Atrial Fibrillation Ablation Quality of Life 105

HeartRhythm

JANUARY 27, 2025

The results of pulmonary vein isolation are limited by arrhythmia recurrence, which is most often due to a failure to effectuate a durable contiguous circumferential transmural lesion around the pulmonary vein (PV) ostia.

Pulmonary 40

Pulmonary Ablation Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Low voltage area (LVA) and low conduction velocity (CV) are promising risk factors to identify patients with abnormal atrial substrate at a high risk of atrial fibrillation (AF) recurrence following pulmonary vein isolation (PVI).

Pulmonary 40

Pulmonary Atrial Fibrillation Arrhythmia Risk Factors 40

HeartRhythm

APRIL 30, 2024

Atrial arrhythmias (AA) are common in patients with pulmonary disease and various cancers. However, the association between AA and non-small cell lung cancer (NSCLC), and the impact of AA on overall clinical outcome in patients with NSCLC are not well-known.

Cancer 40

Cancer Arrhythmia Pulmonary Outcomes 40

HeartRhythm

AUGUST 27, 2024

Figure 1 shows the chest radiograph of the first patient diagnosed with amiodarone pulmonary toxicity back in 1978.1 Amiodarone had been in use for the treatment of cardiac arrhythmias for more than a decade by the time we first identified a potential association of amiodarone therapy and pulmonary toxicity.1

Pulmonary 40

Pulmonary Myocardial Infarction Arrhythmia 40

HeartRhythm

APRIL 30, 2024

Recurrent arrhythmia post PVI is most often secondary to pulmonary vein (PV) reconnections. The evidence on use of adenosine triphosphate (ATP) vs. isoproterenol (ISO) during PVI to reduce recurrence of arrhythmia is conflicting.

Arrhythmia 40

Arrhythmia Pulmonary 40

HeartRhythm

JANUARY 7, 2025

Patients with D-transposition of the great arteries (D-TGA) palliated with atrial switch often develop atrial arrhythmias (AA) requiring pulmonary venous atrium (PVA) access for ablation, which can be achieved via retrograde aortic approach (RAA) or trans-baffle access (TBA).13

Arrhythmia 45

Arrhythmia Aortic Ablation Pulmonary 45

MIBHS

OCTOBER 31, 2024

Arrhythmias (Irregular Heartbeats) Persistent abnormal heart rhythms can disrupt the heart’s pumping efficiency, eventually causing it to enlarge to maintain blood flow. Blood Clots: An enlarged heart is more prone to developing blood clots, which can lead to stroke or pulmonary embolism.

Blood Pressure 52

Blood Pressure Blood Clot Heart Valves Heart Rhythm 52

HeartRhythm

JANUARY 29, 2024

With the advent of self-expanding transcatheter valves that can be safely deployed into the native RVOT, it is now possible to avoid repeat cardiac operations to address progressive pulmonary valve dysfunction.

Pulmonary 40

Pulmonary Congenital Heart Disease Arrhythmia Congenital 40

DAIC

MARCH 28, 2024

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. Pulmonary vein isolation (PVI) was achieved using the VARIPULSE Platform. Food & Drug Administration ( FDA ).

Atrial Fibrillation 110

Atrial Fibrillation AFIB Ablation Pulmonary 110

Heart BMJ

APRIL 25, 2024

Objective To examine the risk of adverse cardiovascular (CV) events following an exacerbation of chronic obstructive pulmonary disease (COPD). The primary outcome was the composite of all-cause death or a first hospitalisation for acute coronary syndrome, heart failure (HF), arrhythmia or cerebral ischaemia. years and 51.7%

Pulmonary 52

Pulmonary Heart Failure Risk Factors Arrhythmia 52

Frontiers in Cardiovascular Medicine

JANUARY 31, 2024

Background Pulmonary vein isolation with wide antral ablation leads to better clinical outcomes for the treatment of atrial fibrillation, but the isolation lesion is invisible in conventional cryoballoon ablation. The primary outcome was a clinical recurrence of documented atrial arrhythmias for >30 s during the 1-year follow-up.

Atrial Fibrillation 64

Atrial Fibrillation Ablation Pulmonary Outcomes 64

Journal of Cardiovascular Electrophysiology

MARCH 17, 2025

Young adults had a higher proportion of FAT originating from the superior vena cava and pulmonary veins. After a mean follow-up of 47.2 months, FAT recurred in 57 patients.

Tachycardia 40

Tachycardia Ablation Outcomes Tricuspid 40

DAIC

APRIL 18, 2024

This forms the physiologic rationale for the accepted convention of a three-month blanking period, during which arrhythmia recurrences are presumed to be relatively benign and not indicative of treatment failure. However, this reasoning disregards valuable data regarding early arrhythmia recurrences and their potential significance.

Atrial Fibrillation 111

Atrial Fibrillation Ablation Heart Rhythm Article 111

HeartRhythm

APRIL 30, 2024

Animal studies suggest that catheter ablation-associated parasympathetic and sympathetic denervation could result in increased ventricular arrhythmias (VA). The impact of catheter ablation of atrial fibrillation on VA burden in humans has not been assessed.

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Ablation Pulmonary 40

Journal of Cardiovascular Electrophysiology

DECEMBER 10, 2024

Objective We report the feasibility, safety, and clinical efficacy of focal monopolar PFA in patients with the origin of their atrial arrhythmia in the SVC. Conclusions In this patient cohort with SVC-triggered atrial arrhythmia, isolation using focal monopolar PFA was feasible, effective, and safe.

Arrhythmia 40

Arrhythmia Ablation Pulmonary Tachycardia 40

Circulation: Arrhythmia and Electrophysiology

JANUARY 29, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. BACKGROUND:High-power short-duration ablation has shown impressive efficacy and safety for pulmonary vein isolation (PVI); however, initial efficacy results with very high power short-duration ablation were discouraging. No complications occurred.

Electrophysiology 76

Electrophysiology Atrial Fibrillation Pulmonary Ablation 76

HeartRhythm

APRIL 30, 2024

Multiple randomized controlled trials (RCTs) have compared the efficacy of pulmonary vein isolation (PVI) adjunctive techniques with PVI alone in patients with persistent atrial fibrillation (AF).

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Arrhythmia 40

Journal of Cardiovascular Electrophysiology

OCTOBER 19, 2023

Although the QDOT MICRO™ Catheter was mainly designed for pulmonary vein isolation (PVI) its versatility to treat atrial fibrillation (AF) and other types of arrhythmias was recently evaluated by the FAST and FURIOUS study series and other studies and will be presented in this article.

Arrhythmia 40

Arrhythmia Ablation Atrial Flutter Atrial Fibrillation 40

Dr. S. Venkatesan MD

APRIL 28, 2024

Both atria develop from a combination of the primitive atrium, sinus venous, and pulmonary veins.It Spatial relationship of sites for atrial fibrillation drivers and atrial tachycardia in patients with both arrhythmias July 2017 International Journal of Cardiology 248(3) AF begets AF. Let us see few factors. References Nil ,

Atrial Fibrillation 75

Atrial Fibrillation Bicuspid/Mitral Pulmonary Ablation 75

European Journal of Heart Failure

FEBRUARY 25, 2025

PVI, pulmonary vein isolation. Herein we describe the effects of catheter ablation on AF burden, arrhythmia recurrences, and ventricular function in end-stage HF. Overall, 97 patients received ablation; 66 patients (68%) underwent pulmonary vein isolation (PVI) and 31 patients (32%) were treated with PVI and additional ablation.

Atrial Fibrillation 40

Atrial Fibrillation Ablation Heart Failure Arrhythmia 40

All About Cardiovascular System and Disorders

MARCH 29, 2024

One is ventricular septal defect, second is overriding aorta, third is pulmonary stenosis, usually right ventricular outflow tract stenosis and associated right ventricular hypertrophy. Pulmonary stenosis, which is usually right ventricular outflow tract stenosis. This will almost invariably result in severe pulmonary regurgitation.

Sudden Cardiac Death 52

Sudden Cardiac Death Pulmonary Stenosis Arrhythmia 52

Circulation: Arrhythmia and Electrophysiology

NOVEMBER 3, 2023

Circulation: Arrhythmia and Electrophysiology, Volume 16, Issue 11 , Page e012043, November 1, 2023. BACKGROUND:In patients with persistent atrial fibrillation (PersAF), catheter ablation aiming for pulmonary vein isolation (PVI) is associated with moderate clinical effectiveness.

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Quality of Life Ablation 40

Circulation: Arrhythmia and Electrophysiology

MARCH 21, 2025

Circulation: Arrhythmia and Electrophysiology, Ahead of Print.

Atrial Fibrillation 40

Atrial Fibrillation Electrophysiology Arrhythmia Pulmonary 40

DAIC

DECEMBER 29, 2023

Unlike paroxysmal AF, which describes symptoms that last for seven days or fewer, persistent AF is a sustained arrhythmia that lasts for more than a week 1. Early treatment of persistent AF can reduce the risk of blood clots, stroke, and heart failure, and may prevent the disease from becoming permanent.

Atrial Fibrillation 115

Atrial Fibrillation Ablation Atrial Flutter Blood Clot 115

DAIC

JULY 24, 2024

Volta Medical has announced it has entered into a Joint Development Agreement with GE Healthcare to enhance arrhythmia procedures with artificial intelligence (AI)-driven electrophysiology technologies. 1 Approximately 33 million patients worldwide are living with AFib.

Atrial Fibrillation 105

Atrial Fibrillation AFIB Ablation Technology 105

HeartRhythm

NOVEMBER 21, 2024

2 BB area pacing defined using P-wave criteria has been associated with decreased atrial arrhythmia burden, recurrence, and de novo incidence compared with right atrial septal pacing and right atrial appendage pacing.3

Pulmonary 40

Pulmonary Atrial Fibrillation Arrhythmia 40

HeartRhythm

APRIL 30, 2024

The approach for recurrent persistent AF, beyond pulmonary vein isolation, remains contentious. Despite advances, catheter ablation success rates for persistent AF remain at 50-60%. Surgical maze procedures have demonstrated superior outcomes compared to catheter ablation.

Ablation 40

Ablation Arrhythmia Pulmonary Outcomes 40

Journal of Cardiovascular Electrophysiology

DECEMBER 7, 2023

Abstract Background The newly introduced nonthermal pulsed field ablation (PFA) is a promising technology to achieve fast pulmonary vein isolation (PVI) with high acute success rates and good safety features. Two tamponades occurred in the PFA while in VHPSD two pts suffered groin bleedings.

Ablation 40

Ablation Pulmonary Arrhythmia Atrial Fibrillation 40

HeartRhythm

FEBRUARY 15, 2024

Pulmonary vein isolation (PVI) has been established as a cornerstone therapy for atrial fibrillation (AF). 1 Several studies have highlighted the significant role of non-pulmonary premature atrial complexes (non-PV PACs) in triggering AF/AT episodes.2,3

Atrial Fibrillation 40

Atrial Fibrillation Arrhythmia Pulmonary Ablation 40

Circulation: Arrhythmia and Electrophysiology

DECEMBER 19, 2024

Circulation: Arrhythmia and Electrophysiology, Ahead of Print. The primary end point was any documented atrial arrhythmia lasting 30 seconds after a 3-month blanking period after ablation. to 3.4%]; hazard ratio, 0.66 [95% CI, 0.460.94]).

Atrial Fibrillation 40

Atrial Fibrillation Ablation Arrhythmia Pulmonary 40

HeartRhythm

JANUARY 6, 2025

1 PFA is conventionally used for pulmonary vein isolation (PVI), but interest has arisen in delivering linear lesions to the posterior wall2 and mitral isthmus.3 Pulsed field ablation (PFA) is a novel modality shown to be safe and efficient.1 3 The durability of these lesion sets has not been well evaluated.

Electrophysiology 40

Electrophysiology Bicuspid/Mitral Arrhythmia Pulmonary 40

HeartRhythm

JANUARY 29, 2024

AF research predominantly focuses on the LA due to two key paradigms: Firstly, the well-established view that AF onset is primarly triggered by activity originating in the pulmonary veins (PVs) of the LA [1].

Arrhythmia 40

Arrhythmia Atrial Fibrillation Pulmonary Research 40

Frontiers in Cardiovascular Medicine

JULY 16, 2024

BackgroundAmiodarone is a class III antiarrhythmic drug that is commonly used in the clinic to treat ventricular arrhythmias and atrial fibrillation. However, its long-term use is associated with serious adverse effects, including thyroid dysfunction, liver injury, and pulmonary toxicity, necessitating careful monitoring and management.

Atrial Fibrillation 52

Atrial Fibrillation Chest Pain Arrhythmia Pulmonary 52

Journal of Cardiovascular Electrophysiology

MARCH 6, 2024

This novel cryoballoon with adjustable size and low compliance successfully achieves pulmonary vein isolation to treat paroxysmal atrial fibrillation (PAF), providing more options for patients with PAF. This cryoballoon system was proven to be safe and effective for treatment of patients with drug refractory or drug intolerant PAF.

Pulmonary 40

Pulmonary Atrial Fibrillation Outcomes Document 40